Immune combo shows promise in aggressive brain tumor trial

NCT ID NCT04606316

Ongoing Disease control Sponsor: Patrick Wen, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether giving two immune-boosting drugs (nivolumab and ipilimumab) before surgery can help fight recurrent glioblastoma, a fast-growing brain cancer. About 63 adults whose tumor has returned after standard treatment will receive the drugs or a placebo before their scheduled surgery. The main goals are to check safety and measure immune cell activity in the tumor tissue removed during surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GBM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GBM GLIOBLASTOMA GLIOBLASTOMA MULTIFORME GRADE IV ASTROCYTOMA

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Stanford University

Stanford, California, 94305, United States
University of California Los Angeles

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.